scholarly journals Immunohistochemistry on cell blocks a method for pre-operative diagnosis of papillary thyroid carcinoma by FNAC

2018 ◽  
Vol 60 (2) ◽  
pp. 102-104
Author(s):  
Hussain A. Aljebori
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Reliable Method ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Highly Sensitive ◽  
Bethesda System

Background: Papillary thyroid carcinoma (PTC) is the commonest thyroid cancer. Cases in category-5a of Bethesda system (suspicious for papillary carcinoma) are treated by surgical lobectomy followedby total thyroidectomy if histopathology confirms papillary carcinoma. In order to reduce surgicalprocedures to one this was conducted.Objectives: evaluation of role of immunohistochemistry in pre-operative diagnosis of papillary thyroidcarcinoma on cell blocks.Materials and Method: Cell blocks were taken from cases labelled category-5a for histopathology andimmunohistochemistry using three markers (CK-19, Thyro-peroxidase, and BRAFv600E mutation).Results: were highly sensitive, and specific. The use of more than markers increases sensitivity of theprocedure.Conclusion: immunohistochemical stains on cell blocks is a reliable method for pre-operative diagnosisof papillary thyroid carcinoma.

scholarly journals Immunohistochemistry on cell blocks a method for pre-operative diagnosis of papillary thyroid carcinoma by FNAC

2018 ◽  
Vol 60 (2) ◽  
pp. 102-104
Author(s):  
Hussain A. Aljebori
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Reliable Method ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Highly Sensitive ◽  
Bethesda System

Background: Papillary thyroid carcinoma (PTC) is the commonest thyroid cancer. Cases in category-5a of Bethesda system (suspicious for papillary carcinoma) are treated by surgical lobectomy followedby total thyroidectomy if histopathology confirms papillary carcinoma. In order to reduce surgicalprocedures to one this was conducted.Objectives: evaluation of role of immunohistochemistry in pre-operative diagnosis of papillary thyroidcarcinoma on cell blocks.Materials and Method: Cell blocks were taken from cases labelled category-5a for histopathology andimmunohistochemistry using three markers (CK-19, Thyro-peroxidase, and BRAFv600E mutation).Results: were highly sensitive, and specific. The use of more than markers increases sensitivity of theprocedure.Conclusion: immunohistochemical stains on cell blocks is a reliable method for pre-operative diagnosisof papillary thyroid carcinoma.

scholarly journals Warthin-Like Papillary Carcinoma of the Thyroid Gland: Case Report and Review of the Literature

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Panagiotis Paliogiannis ◽  
Federico Attene ◽  
Federica Trogu ◽  
Mario Trignano
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Gland ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Histopathological Examination ◽  
Lymph Node Involvement ◽  
Papillary Thyroid ◽  
Review Of The Literature

We present a case of Warthin-like papillary thyroid carcinoma in a 22-year-old woman and a review of the literature on the topic. The patient had the occasional discovery of a hypoechoic thyroid nodule of approximately 18 mm, characterized by irregular margins, hyperechoic spots, rich intra- and perilesional vascularization, and a suspicious enlarged right laterocervical lymph node. Fine-needle aspiration was performed for both lesions and the diagnosis of papillary thyroid carcinoma without lymph node involvement was made. The patient underwent thyroidectomy and central neck lymphadenectomy without complications. Histopathological examination suggested a Warthin-like papillary carcinoma of the thyroid gland, with all the removed lymph nodes being free of disease. The patient subsequently underwent iodine ablative therapy and she remains free of disease one year after surgery. Warthin-like papillary thyroid carcinoma is a recently described variant of papillary thyroid cancer that is frequently associated with lymphocytic thyroiditis. Morphologically, it resembles Warthin tumors of the salivary glands, with T and B lymphocytes infiltrating the stalks of papillae lined with oncocytic cells. Surgical and postoperative management is identical to that of classic differentiated thyroid cancer, while prognosis seems to be favourable.

Role of BRAFV600E Mutation as a Marker for Prognostic Stratification of Papillary Thyroid Carcinoma

2014 ◽  
Vol 14 (3) ◽  
pp. 150
Author(s):  
Taek Ju Kwon ◽  
Jino Baek ◽  
Jiyeon Lee ◽  
Jin Gu Kang ◽  
Seung Ook Hwang ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Prognostic Stratification

scholarly journals mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma

2012 ◽  
Vol 97 (7) ◽  
pp. E1139-E1149 ◽  
Author(s):  
Alexandra Faustino ◽  
Joana P. Couto ◽  
Helena Pópulo ◽  
Ana Sofia Rocha ◽  
Fernando Pardal ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Cell Lines ◽  
Genetic Alterations ◽  
Mtor Pathway ◽  
Expression Vectors ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Pathway Activation

Abstract Context: There are several genetic and molecular evidences suggesting dysregulation of the mammalian target of rapamycin (mTOR) pathway in thyroid neoplasia. Activation of the phosphatidylinositol-3-kinase/AKT pathway by RET/PTC and mutant RAS has already been demonstrated, but no data have been reported for the BRAFV600E mutation. Objective: The aim of this study was to evaluate the activation pattern of the mTOR pathway in malignant thyroid lesions and whether it may be correlated with known genetic alterations, as well as to explore the mechanisms underlying mTOR pathway activation in these neoplasias. Results: We observed, by immunohistochemical evaluation, an up-regulation/activation of the mTOR pathway proteins in thyroid cancer, particularly in conventional papillary thyroid carcinoma (cPTC). Overactivation of the mTOR signaling was particularly evident in cPTC samples harboring the BRAFV600E mutation. Transfection assays with BRAF expression vectors as well as BRAF knockdown by small interfering RNA revealed a positive association between BRAF expression and mTOR pathway activation, which appears to be mediated by pLKB1 Ser428, and emerged as a possible mechanism contributing to the association between BRAF mutation and mTOR pathway up-regulation. When we evaluated the rapamycin in the growth of thyroid cancer cell lines, we detected that cell lines with activating mutations in the MAPK pathway show a higher sensitivity to this drug. Conclusions: We determined that the AKT/mTOR pathway is particularly overactivated in human cPTC harboring the BRAFV600E mutation. Moreover, our results suggest that the mTOR pathway could be a good target to enhance therapy effects in certain types of thyroid carcinoma, namely in those harboring the BRAFV600E mutation.

Prognostic role of the Bethesda System for conventional papillary thyroid carcinoma

Head & Neck ◽  
2016 ◽  
Vol 38 (10) ◽  
pp. 1509-1514 ◽  
Author(s):  
Hye Mi Gweon ◽  
Hye Ryoung Koo ◽  
Eun Ju Son ◽  
Jeong-Ah Kim ◽  
Ji Hyun Youk ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Prognostic Role ◽  
Bethesda System ◽  
The Bethesda System

scholarly journals IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma

2019 ◽  
Vol 104 (11) ◽  
pp. 5573-5584 ◽  
Author(s):  
Siao Ting Chong ◽  
Khee Ming Tan ◽  
Catherine Y L Kok ◽  
Shou Ping Guan ◽  
Siang Hui Lai ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Cell Migration ◽  
Thyroid Cancer ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Cell Lines ◽  
Papillary Thyroid ◽  
Thyroid Carcinomas ◽  
Advanced Tumor

Abstract Context The interleukin-13 receptor alpha2 (IL13RA2), which is known to be overexpressed in glioblastoma multiforme, plays a role in various cellular processes such as cell migration that may contribute to tumor progression. Studies have attributed IL13RA2 to invasion and metastasis in cancers of the ovary, breast, and pancreas, but the pathological role of IL13RA2 in thyroid cancer is still unclear. Objective This study aims to evaluate IL13RA2 expression in thyroid carcinomas and to examine the role of IL13RA2 in the progression of papillary thyroid carcinoma (PTC). Methods IL13RA2 immunochemical staining was performed on tissue microarrays of 137 thyroid carcinomas from patients, and the differential profile of IL13RA2 was validated in thyroid cancer cell lines. In PTC cell lines, we functionally assessed the effects of IL13RA2 underexpression and overexpression on cell proliferation, cell migration, and epithelial-mesenchymal transition (EMT) by using CCK-8, transwell migration assay, quantitative RT-PCR, and Western blot analysis. Results IL13RA2 expression was significantly correlated with advanced tumor T stage (pT3 or pT4; P = 0.001) and regional lymph node metastasis (pN1; P < 0.001). The staining scores of IL13RA2 were significantly higher in PTC compared with follicular subtypes (P < 0.001) and correlated with advanced tumor stage among PTC samples (pT3 or pT4; P = 0.028). Knockdown of IL13RA2 in B-CPAP cells significantly reduced cell viability, cell migration, and EMT markers including N-cadherin, Vimentin, and Snail. Exogenous overexpression of IL13RA2 in K1 cells increased cell migration and EMT, although cell proliferation was not affected. Conclusion IL13RA2 is differentially regulated in PTC and is involved in cell migration by enhancing EMT.

scholarly journals Platelet-activating factor and human thyroid cancer

2005 ◽  
Vol 153 (1) ◽  
pp. 31-40 ◽  
Author(s):  
Yves Denizot ◽  
Thierry Chianéa ◽  
François Labrousse ◽  
Véronique Truffinet ◽  
Manuela Delage ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Gland ◽  
Thyroid Carcinoma ◽  
Platelet Activating Factor ◽  
Human Thyroid ◽  
Papillary Thyroid ◽  
Benign Adenoma ◽  
Paf Receptor

Objective: Platelet-activating factor (PAF) is a pro-inflammatory and angiogenic lipid mediator involved in several types of cancer in humans. The levels of PAF, lyso-PAF (the PAF precursor), phospholipase A2 activity (PLA2, the enzymatic activity implicated in lyso-PAF formation) and acetylhydrolase activity (AHA, the PAF-degrading enzyme) were investigated in various diseased thyroid tissues. Subjects: Control and diseased tissue of patients with a hyperplastic goitre (n = 14), a benign adenoma (n = 12) and a papillary thyroid carcinoma (n = 15) were investigated. Results: PAF receptor transcripts were found in the human thyroid tissue. PAF, lyso-PAF, PLA2 and AHA were present in control thyroid tissues, their levels being significantly correlated with each other, suggesting tiny regulations of the PAF metabolic pathways inside the thyroid gland. PAF, lyso-PAF, PLA2 and AHA levels remained unchanged in diseased tissues of patients with a hyperplastic goitre, a benign adenoma and a papillary thyroid carcinoma. No difference was found between PAF, lyso-PAF, PLA2 and AHA levels with respect to the TNM tumour status and the histological sub-type of papillary thyroid carcinoma. No correlation was found between tissue PAF levels and those of vascular endothelial growth factor and basic fibroblast growth factor, two angiogenic growth factors involved in thyroid cancer and that mediate their effect through PAF release in breast and colorectal cancer. Conclusion: PAF, PAF receptor transcripts and the enzymatic activities implicated in PAF production and degradation are present in the thyroid gland. While the physiological role of PAF is presently unknown in thyroid physiology, this study highlights no evidence for a potentially important role of PAF during human thyroid cancer, a result that markedly differs from breast and colorectal ones.

Sign in / Sign up

Export Citation Format

Share Document